News
12 March 2021
Endobios has just published the first scientific manuscript related to its disruptive R&D in endosymbioses (core IP undisclosed):
“A potential third‐order role of the host endoplasmic reticulum as a contact site in interkingdom microbial endosymbiosis and viral infection”
https://sfamjournals.onlinelibrary.wiley.com/doi/10.1111/1758-2229.12938
23 October 2020
ENDOBIOS will present the pitch of its preclinical asset against epilepsy, at the Bio-Europe 2020 conference, integrated in the EIT Health Innostars Awards Grand Final.
https://informaconnect.com/bioeurope/speakers/celso-almeida/
16 June 2020
ENDOBIOS was shortlisted in the preselection phase of the Innovation Awards Roullier 2020, as a recognition of our proprietary method for the induction of cryptic antibiotics from microbial culturable sources (fungi, bacteria, microalgae), applicable in the agro, pharma or cosmetics industry.
9 June 2020
ENDOBIOS received an Innostars 2020 Award (EIT Health, European Union), as a recognition of our project related to the preclinical development of a marine-derived natural product as a drug candidate against epilepsy.
https://eithealth.eu/news-article/innostars-awards-comes-back-with-its-2020-semi-finalists/
15 August 2019
ENDOBIOS is now eligible to apply for NIH grants (USA) as a foreign institution, after completing the registration procedures in the DUNS, SAM.gov, eRA Commons, Grants.gov and NATO-NCAGE systems.